Literature DB >> 32622879

Quadriceps Strength and Mortality in Older Patients With Heart Failure.

Takeshi Nakamura1, Kentaro Kamiya2, Nobuaki Hamazaki3, Ryota Matsuzawa4, Kohei Nozaki3, Takafumi Ichikawa3, Masashi Yamashita5, Emi Maekawa6, Jennifer L Reed7, Chiharu Noda6, Kentaro Meguro6, Minako Yamaoka-Tojo8, Atsuhiko Matsunaga8, Junya Ako6.   

Abstract

BACKGROUND: This study was performed to test the hypothesis that low quadriceps isometric strength (QIS) is associated with greater risk of mortality and has the additive prognostic significance to the severity of heart failure (HF) and gait speed in older patients with HF.
METHODS: A retrospective cohort study was performed in 1273 patients ≥ 60 years of age with HF (mean age 75 ± 8 years, 59.1% men); all of whom were evaluated during hospitalization for usual gait speed and maximal QIS. The QIS was expressed relative to body mass (% BM). The endpoint was all-cause mortality.
RESULTS: Over a median follow-up period of 1.59 years (interquartile range, 0.58 to 3.42 years), 224 patients died. The cutoff value based on the Youden index for the QIS discriminating those at high risk of mortality was 36.2% BM for overall, and we defined less than this cutoff point of QIS as low QIS. After adjustment for the HF risk score, the hazard ratio in low QIS was 1.55 for overall (95% confidence interval [CI], 1.17-2.06). The addition of low QIS to the HF risk score and gait speed was associated with significant increases in both net reclassification improvement (NRI, 0.239 for overall; 95% CI, 0.096-0.381) and integrated discrimination improvement (IDI, 0.004 for overall; 95% CI, 0.001-0.009) for all-cause mortality.
CONCLUSION: Low QIS was strongly associated with poor prognosis and showed complementary prognostic predictive capability to the HF risk score and gait speed in older patients with HF.
Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32622879     DOI: 10.1016/j.cjca.2020.06.019

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  5 in total

1.  Examining the role of sex on the benefits of muscle-strengthening activities for people living with obesity: A cross-sectional study.

Authors:  Mohammad Keshavarz; Martin Sénéchal; Stephan U Dombrowski; Daniel Meister; Danielle R Bouchard
Journal:  Health Sci Rep       Date:  2022-07-04

2.  Associations between kidney function and outcomes of comprehensive cardiac rehabilitation in patients with heart failure.

Authors:  Nobuaki Hamazaki; Kentaro Kamiya; Shohei Yamamoto; Kohei Nozaki; Takafumi Ichikawa; Ryota Matsuzawa; Masashi Yamashita; Shota Uchida; Emi Maekawa; Kentaro Meguro; Minako Yamaoka-Tojo; Atsuhiko Matsunaga; Junya Ako
Journal:  Clin Res Cardiol       Date:  2021-05-31       Impact factor: 5.460

3.  Efficacy and Safety of Acute Phase Intensive Electrical Muscle Stimulation in Frail Older Patients with Acute Heart Failure: Results from the ACTIVE-EMS Trial.

Authors:  Shinya Tanaka; Kentaro Kamiya; Yuya Matsue; Ryusuke Yonezawa; Hiroshi Saito; Nobuaki Hamazaki; Ryota Matsuzawa; Kohei Nozaki; Masashi Yamashita; Kazuki Wakaume; Yoshiko Endo; Emi Maekawa; Minako Yamaoka-Tojo; Takaaki Shiono; Takayuki Inomata; Junya Ako
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-27

Review 4.  Effectiveness and Approach of Rehabilitation in Patients With Acute Heart Failure: A Review.

Authors:  Kensuke Ueno; Hidehiro Kaneko; Hidetaka Itoh; Norifumi Takeda; Hiroyuki Morita; Katsuhito Fujiu; Kentaro Kamiya; Issei Komuro
Journal:  Korean Circ J       Date:  2022-08       Impact factor: 3.101

5.  Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus.

Authors:  Ayuko Kashima; Kentaro Kamiya; Nobuaki Hamazaki; Kensuke Ueno; Kohei Nozaki; Takafumi Ichikawa; Masashi Yamashita; Shota Uchida; Takumi Noda; Kazuki Hotta; Emi Maekawa; Minako Yamaoka-Tojo; Atsuhiko Matsunaga; Junya Ako
Journal:  J Clin Med       Date:  2022-10-09       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.